Ozempic, Mounjaro mania: Can employers afford the weight-loss revolution?
Published November 3, 2026|1 min read
Share via
In this article
Employers face rising GLP-1 demand. Here are tips to manage costs while maintaining care access.
As GLP-1 medications like Ozempic and Mounjaro gain traction for managing diabetes and obesity, employers face escalating costs and complex coverage decisions.
In this article, Janet Young, M.D., Clinical Analytics Advisor at Springbuk, examines how organizations can navigate this evolving landscape.
Rising GLP-1 Utilization: Employer spending on GLP-1 drugs has surged 272% over four years, now comprising nearly 16% of total prescription drug costs
Understanding Usage Patterns: While media spotlight weight loss, most GLP-1 prescriptions are for employees managing type 2 diabetes, with obesity-related claims increasing but still secondary.
Cost-Benefit Analysis: Employers must weigh immediate budget impacts against potential long-term health improvements and cost savings from reduced complications
Strategic Cost Management: Implementing step therapy, prior authorization, and quantity limits can help control expenses while ensuring appropriate access
Employee Engagement: Educating employees on lifestyle modifications and providing alternative programs can complement pharmacological treatments and enhance outcomes
Ready for a consultation?
Our team is ready to answer your questions. Let's make smarter health ecosystems, together.